Comparison of Major-Bleeding Risk and Health Care Costs Among Treatment-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin
No Thumbnail Available
Date
2015
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Open Access Color
OpenAIRE Downloads
OpenAIRE Views
Abstract
...
Description
Onur Başer (MEF Author)
##nofulltext##
##nofulltext##
Keywords
Turkish CoHE Thesis Center URL
Fields of Science
Citation
Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. (November 7-11, 2015). Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. American Heart Association (AHA) Scientific Sessions 2015. Orlando, FL.
WoS Q
Scopus Q
Source
American Heart Association (AHA) Scientific Sessions 2015
